Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

- Female or male, 30 to 60 years of age

- Bilateral lateral canthal lines rated as moderate or severe

- Willing to refrain from receiving facial fillers, laser treatments, use of any product that affects skin remodeling or a product that may cause an active dermal response in the treatment area beginning at Screening and through End of Study

- Women of childbearing potential must be practicing and willing to continue to use an effective method of birth control during the course of the study

- Muscle weakness or paralysis in the area receiving study treatment -Active skin disease or irritation at the treatment areas

- Undergone any procedures that may affect the lateral canthal region during the past 12 months prior to Screening

- Use of a topical steroid on either of the treatment areas or use of medications that suppress the immune system 30 days prior to Screening and continuing through End of Study (Day 28)

- Any abnormality on the electrocardiogram (ECG) at Screening or any history of clinically significant arrhythmia, unstable angina, myocardial infarction or congestive heart failure.

- Previous treatment with Botulinum Toxin Type A in the face area